Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Post by Turtle4on Jun 15, 2023 10:36am
266 Views
Post# 35497975

Don't waste time with individual license agreements for TFC1

Don't waste time with individual license agreements for TFC1
This is about costmetics and not about pharma, where license agreements are common. But for such a large cosmetics market, an exclusive license agreement is nonsense!
 
Sirona should do the following:
- Give TFC1326 a brand name.
- Prepare simple standard license agreements. Something upfront + annual fixed license fee (which could be e.g. staggered according to annual sales).
- Sell the stuff with high costs per unit (because no royalties, that would be more complicated again)
 
Then everyone who meets the license conditions (upfront, annual fee, brand name on the product etc.) can start immediately. And who is too slow (like abbvie with TFC1067) loses market share. Boom!
<< Previous
Bullboard Posts
Next >>